Immunocore Holdings plc (IMCR) Cash Flow Statement
Immunocore Holdings plc (IMCR) generated -$35.0M of operating cash flow over the twelve months to 2026-06-30, spent $6.2M on capital expenditure and had free cash flow of -$41.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMCRImmunocore Holdings plcFollow IMCR — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | 0.00 | 0.03 | -0.01 | -0.03 | |
| Capital expenditure | 0.01 | 0.01 | 0.00 | -0.01 | |
| Free cash flow | -0.00 | 0.02 | -0.02 | -0.04 | |
| Stock-based compensation | 0.03 | 0.03 | 0.04 | — |
USD billions · SEC XBRL
Immunocore Holdings plc — questions
- What is Immunocore Holdings plc's operating cash flow?
- -$35.0M over the twelve months to 2026-06-30.
- How much does Immunocore Holdings plc spend on capital expenditure?
- $6.2M over the twelve months to 2026-06-30.
- What is Immunocore Holdings plc's free cash flow?
- -$41.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Immunocore Holdings plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.